Vidal François-Xavier, Gil Julie, Gregson Maud, Zeder-Lutz Gabrielle, Hideux Maria, Lemoine Jérôme, Krimm Isabelle, Wagner Renaud, Dugas Vincent, Demesmay Claire
Universite Claude Bernard Lyon1, ISA, UMR5280, CNRS, 5 rue de la Doua, Villeurbanne, 69100, France.
Plateforme IMPReSs, CNRS UAR3286, Plateforme de chimie biologique intégrative de Strasbourg, Ecole Supérieure de Biotechnologie de Strasbourg, Illkirch, France.
Anal Chim Acta. 2025 Jun 1;1353:343950. doi: 10.1016/j.aca.2025.343950. Epub 2025 Mar 17.
Membrane proteins, which make up approximately 30 % of the proteome, are important drug targets but present many challenges in drug discovery, including limited production rates, low final yields of pure and functionally folded proteins, and instability in aqueous media. The problems encountered with membrane proteins are even more critical in the Fragment Based Drug Discovery, where the discovery of potential drug candidates is hampered by the limited availability of efficient methods for rapid screening of weak fragment-protein interactions.
In this work, we propose the coupling of miniaturized weak affinity chromatography with mass spectrometry (nano-WAC-MS) as an innovative strategy for the rapid screening of fragments capable of weak binding to a selected membrane protein. An integral membrane protein (AAR) was incorporated into biotinylated nanodiscs, which were subsequently immobilized on a miniaturized monolithic streptavidin column (75 μm i.d., 300 nL volume). The coupling of these miniaturized affinity columns (each consuming less than 1 μg of protein) to mass spectrometry (MRM mode) has been optimized to maximize the low affinity range and increase throughput so that 150 fragments can be injected in a single analysis, with a DMSO content as high as 10 %, with no influence on the affinity. Hits are identified by comparing their retention with that measured on control columns prepared with empty nanodiscs.
The results of this screening are compared with those obtained by NMR and newly identified hits are confirmed by either competition experiments or frontal affinity experiments. We show that this nanodisc-based strategy, which provides a stable and native-like lipid environment for the protein (columns can be used for several days), should also work with other membrane proteins embedded in nanodiscs.
膜蛋白约占蛋白质组的30%,是重要的药物靶点,但在药物研发中面临诸多挑战,包括生产率有限、纯的且功能折叠的蛋白质最终产量低以及在水性介质中不稳定。在基于片段的药物发现中,膜蛋白所遇到的问题更为关键,因为用于快速筛选弱片段 - 蛋白质相互作用的有效方法有限,阻碍了潜在药物候选物的发现。
在这项工作中,我们提出将小型化弱亲和色谱与质谱联用(纳米 - WAC - MS),作为一种快速筛选能够与选定膜蛋白弱结合的片段的创新策略。将一种整合膜蛋白(AAR)整合到生物素化的纳米盘中,随后将其固定在小型化的整体式链霉亲和素柱(内径75μm,体积300nL)上。已对这些小型化亲和柱(每个消耗少于1μg蛋白质)与质谱(MRM模式)的联用进行了优化,以最大化低亲和力范围并提高通量,从而在单次分析中可以注入150个片段,二甲基亚砜含量高达10%,且对亲和力无影响。通过将其保留时间与用空纳米盘制备的对照柱上测得的保留时间进行比较来鉴定命中片段。
将该筛选结果与通过核磁共振获得的结果进行比较,新鉴定的命中片段通过竞争实验或前沿亲和实验进行确认。我们表明,这种基于纳米盘的策略为蛋白质提供了稳定且类似天然的脂质环境(柱可使用数天),也应该适用于嵌入纳米盘中的其他膜蛋白。